Adalta Ltd has released a press release.
AD-214 Phase I extension study fully enrolled
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from AdAlta
- AdAlta to Present at August 24th Virtual Investor Summit
- AD-214 returns to clinic
- $1.87 million raised in oversubscribed Shortfall facility
- New AD-214 data de-risks clinical studies
- AD-214 clinical trial approval
Later from AdAlta
- Dosing simulations support AD-214 IV product profile
- Prof Foley invited presentation AD-214
- R&D tax refund received & R&D Loan repayment terms extended
- AD-214 well tolerated in Phase I extension study
- Placement to raise up to $1.23million
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta